Is Ultragenyx Pharmaceutical (NASDAQ:RARE) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Ultragenyx Pharmaceutical at current levels.
Four Phase 3 readouts in twelve months on a $2.4B market cap. The setup is asymmetric, the patience required is real.
Where RARE is headed
Ultragenyx walks into 2027 as something it has never been: a rare disease company with a pipeline that has actually delivered. UX143 (setrusumab) for osteogenesis imperfecta is the linchpin. If the Phase 3 Orbit and Cosmic readouts confirm the fracture reduction signal from the open-label data, this is a billion-dollar drug treating brittle bone disease in a population with no approved targeted therapy. Regeneron splits the economics 50/50, but half of a billion-plus franchise on a $2.4B market cap is the whole investment case in one molecule.
Read the full Compass Direction on RARE
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios.
See the full RARE analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Ultragenyx Pharmaceutical (NASDAQ:RARE) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Ultragenyx Pharmaceutical at current levels. Four Phase 3 readouts in twelve months on a $2.4B market cap. The setup is asymmetric, the patience required is real.
What is RARE's Compass Score?
Ultragenyx Pharmaceutical scores 68/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for RARE?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the RARE page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.